CTOs on the Move

Verve Therapeutics

www.vervetx.com

 
Verve Therapeutics is a biotechnology company focused on discovering and developing therapies that safely edit the genomes of adults to confer lifelong protection against coronary artery disease, the most common type of heart disease and the leading cause of death worldwide. Headquartered in Cambridge, Mass., with a research facility in Philadelphia.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Emily Donlon
Senior Director, Information Technology Profile
Andrew Sheely
Vice President Information Technology Profile

Funding

Verve Therapeutics raised $58.5M on 05/07/2019
Verve Therapeutics raised $63M on 06/11/2020
Verve Therapeutics raised $94M on 01/19/2021

Similar Companies

Proteonomix

The mission of Proteonomix, Inc. is to achieve a leadership position in life enhancement regenerative stem cell therapies, services, and products through a combination of first to market technologies, and innovative clinical trial strategies.

89bio

We are a clinical-stage biopharmaceutical company focused on changing the lives of patients living with nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Our teams in the US and Israel are developing highly differentiated medicines that address unmet medical needs based on robust research. Our lead product candidate, BIO89-100, is a novel long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.

Metacrine

We are a clinical-stage biopharmaceutical company focused on discovering and developing best-in-class therapies for patients with liver and gastrointestinal, or GI, diseases. Since our founding in 2014, we have invested in building a foundation of chemistry and biology expertise to drive innovative drug discovery and development. We believe these internal capabilities allow us to gain insights into disease targets and mechanisms and more quickly and purposefully design therapies with characteristics that we view as key to safety and efficacy. With this systematic approach, we have designed novel, proprietary farnesoid X receptor (FXR) clinical product candidates arising from a unique chemical scaffold with the potential to be best-in-class for non-alcoholic steatohepatitis, or NASH, and first- in-class for Inflammatory Bowel Disease, or IBD. In addition to our FXR program, we have continued to invest in drug discovery on other therapeutic targets that have effects on inflammation and/or fibrosis for which we believe we could develop proprietary small molecule therapies.

iCyt Mission Technology

iCyt Mission Technology is a Champaign, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ben Venue Laboratories

Ben Venue Laboratories is a Bedford, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.